Verition Fund Management
AMLX icon

Verition Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Verition Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-75,000
Closed -$213K – 2962
2024
Q1 		$213K Buy
+75,000
New +$981K ﹤0.01% 2469

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Verition Fund Management's AMLX Position: Q1 2026 in Review

Verition Fund Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 55% in Q1 2026, selling an estimated $228K and leaving 13,264 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

Verition Fund Management first reported a position in AMLX in Q1 2022 and has held it in 11 quarters since. The position peaked at $18.3M in Q2 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Verition Fund Management held 13,264 shares of Amylyx Pharmaceuticals worth $184K as of Q1 2026.
  • Verition Fund Management sold 16,223 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $228K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1964 holding.
  • Verition Fund Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
  • Verition Fund Management's Amylyx Pharmaceuticals position peaked at $18.3M in Q2 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.